ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Cancer Claims Morris Kupchan, Who Found Promising New Antitumor Drugs In Plants

October 29, 1976

Study: BRCA2-Negative Women Could Still Have High Risk

December 27, 2013

To Wage New War On Cancer, Advocates Plan A Campaign Inspired By Earth Day

October 31, 1997

An Angel In heaven – Or How Rejected Grants Do and Don’t Get Reviewed

May 3, 1974

James Watkins To Head AIDS Commission Following Mayberry’s Resignation

October 16, 1987

Investigation finds no evidence FDA’s Crawford had affair with subordinate.

June 10, 2005